Premature blood stem cell aging in sickle cell disease may be reversible
A study from St. Jude Children's Research Hospital suggests that premature aging of blood stem cells in sickle cell disease patients may be reversible using senolytic drugs. These drugs target aging-related processes to restore the bone marrow's ability to produce healthy blood cells.
Why it matters
This research offers a potential new therapeutic pathway for managing sickle cell disease, which affects millions globally and currently lacks widespread curative options.
(L to R) First author Aditya Barve, PhD, St. Jude Department of Hematology, co-corresponding author Akshay Sharma, MBBS, MSc, St. Jude Department of Bone Marrow Transplantation & Cellular Therapy, and senior co-corresponding author Shannon McKinney-Freeman, PhD, St. Jude Department of Hematology.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in